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Abstract 
Background: Computer-based technology is becoming increasingly essential in biological research where drug 
discovery programs start with the identification of suitable drug targets. 2-Methoxyestradiol (2ME2) is a 17β-estradiol 
metabolite that induces apoptosis in various cancer cell lines including cervical cancer, breast cancer and multiple 
myeloma. Owing to 2ME2’s poor in vivo bioavailability, our laboratory in silico-designed and subsequently synthe-
sized a novel 2ME2 analogue, 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol), using receptor- and 
ligand molecular modeling. In this study, the biological effects of ESE-15-ol (180 nM) and its parent molecule, 2ME2 
(1 µM), were assessed on morphology and apoptosis induction in cervical cancer cells.
Results: Transmission electron microscopy, scanning electron microscopy and polarization-optical transmitted 
light differential interference contrast (PlasDIC) images demonstrated morphological hallmarks of apoptosis includ-
ing apoptotic bodies, shrunken cells, vacuoles, reduced cell density and cell debris. Flow cytometry analysis showed 
apoptosis induction by means of annexin V-FITC staining. Cell cycle analysis showed that ESE-15-ol exposure resulted 
in a statistically significant increase in the G2M phase (72%) compared to 2ME2 (19%). Apoptosis induction was more 
pronounced when cells were exposed to ESE-15-ol compared to 2ME2. Spectrophotometric analysis of caspase 8 
activity demonstrated that 2ME2 and ESE-15-ol both induced caspase 8 activation by 2- and 1.7-fold respectively indi-
cating the induction of the apoptosis. However, ESE-15-ol exerted all of the above-mentioned effects at a much lower 
pharmacological concentration (180 nM) compared to 2ME2 (1 µM physiological concentration).
Conclusion: Computer-based technology is essential in drug discovery and together with in vitro studies for the 
evaluation of these in silico-designed compounds, drug development can be improved to be cost effective and 
time consuming. This study evaluated the anticancer potential of ESE-15-ol, an in silico-designed compound in vitro. 
Research demonstrated that ESE-15-ol exerts antiproliferative activity accompanied with apoptosis induction at a 
nanomolar concentration compared to the micromolar range required by 2ME2. This study is the first study to dem-
onstrate the influence of ESE-15-ol on morphology, cell cycle progression and apoptosis induction in HeLa cells. In 
silico-design by means of receptor- and ligand molecular modeling is thus effective in improving compound bioavail-
ability while preserving apoptotic activity in vitro.
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Background
Cervical cancer is a leading cause of death for women 
worldwide [1]. Antimitotic compounds are still one 
of the most widely used chemotherapeutic drugs for 
cervical cancer treatment. Chemotherapeutic drugs 
include agents that target the cell cycle resulting in anti-
proliferative activity and subsequent apoptosis induction 
[2, 3].
Microtubule-targeting agents are divided into two tra-
ditional categories: microtubule-destabilizing agents 
such as the vinca alkaloids vinblastine, vincristine and 
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colchicine and microtubule-stabilizing agents such as the 
taxanes (paclitaxel and docetaxel) [4]. Agents that bind to 
the colchicine-binding site of microtubules are in various 
stages of clinical trials and include combretastatins, as 
well as 2-methoxyestradiol (2ME2) [5]. Microtubules are 
essential for cytoskeleton integrity, embryonic develop-
ment, cell division, intracellular molecular transport sys-
tem, gene activation and potentially play a role in cervical 
cancer treatment [6].
2ME2 is a naturally occurring 17β-estradiol metabo-
lite synthesized from sequential hepatic hydroxyla-
tion and methylation by cytochrome P450 enzymes and 
catechol-O-methyltransferase [7]. 2ME2 exerts estro-
gen-independent activity by targeting the microtubule 
skeleton and by inhibiting tumour growth and angio-
genesis. In addition, 2ME2 inhibits the tubulin polym-
erization in  vitro, thus disrupting normal microtubule 
functioning [7]. 2ME2 induces apoptosis by activating the 
intrinsic- and extrinsic cascade by both caspase depend-
ent- and independent pathways [4]. In addition to the 
inhibition of microtubule dynamics and induction of cell 
cycle arrest, the pro-apoptotic activity of 2ME2 has also 
been associated with stimulation of cellular reactive oxy-
gen species (ROS) production, resulting in the release of 
cytochrome c from the mitochondria and activation of 
caspases [7].
In vitro, 2ME2 exerts antiproliferative activity in a wide 
variety of cell lines including tumorigenic estrogen recep-
tor positive MCF-7 breast cancer cells, cervical cancer 
HeLa cells and HCT116 colon cancer cells [7, 8]. 2ME2 
(Panzem®) was evaluated in several phase I and II clini-
cal trials [5]. Therapeutic doses in vivo resulted in a met-
aphase arrest, and, as a consequence, inhibition of cell 
proliferation and induction of apoptosis [7]. Results from 
preclinical tumor models in animals suggest that, main-
taining a plasma concentration of 2ME2 in the range of 
10–56 nM, is required for efficient antitumor activity [9, 
10].
Undesirable biopharmaceutical properties includ-
ing rapid metabolism and low bioavailability of 2ME2 
resulted in identification of estradiol analogues with 
improved in  vivo efficacy. 2ME2 is metabolized with 
conjunction at the 3- and 17 positions, together with 
oxidation at the 17 position [11]. Structure–activity rela-
tionships indicated that the addition of a sulfamate group 
at position 3 of the estradiol backbone improves bio-
availability of estradiol analogues and overcomes rapid 
biodegradation. This improves bioavailability since the 
sulphamate groups are highly reversible inhibitors of 
carbonic anhydrase II [5, 10]. The latter is most likely 
responsible for the high bioavailability of the sulpham-
oylated analogues since reversible uptake by erythro-
cytes and interaction with carbonic anhydrase II ensures 
transiting the liver without undergoing first pass metabo-
lism [5].
It is well-recognised that drug discovery and subsequent 
development is a timely- and expensive process. Com-
puter-based technology that combines chemical- and bio-
logical parameters in order to optimize drug identification, 
development and synthesis. Therefore, computer-based 
methods for identifying potential anticancer compounds 
are becoming increasingly important. These chemico-bio-
logical approaches in computer-based techniques used in 
drug discovery are referred to as in silico methods. Com-
monly used computational approaches include ligand-
binding drug design, structure-based drug design (docking 
studies) and structure-activity relationships [12]. By means 
of docking studies and structure-activity relationships 
our laboratory in silico-designed several 17β-estradiol 
analogues where structure-activity relationships indicate 
enhanced potency and improved bioavailability [3, 5]. 
This study involved one of these novel compounds namely 
2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol 
(ESE-15-ol). Docking studies of ESE-15-ol suggest that the 
selectivity is due to the double bond in the D-ring that is 
capable of interacting with histone 61 of the cancer associ-
ated carbonic anhydrase (CA) IX [3].
CAIX protein expression can be induced in MDA-
MB-231 cells by the iron chelator, desferrioxamine 
mesylate (DFO) in a manner that results in extracellular 
acidification due to CAIX over-expression [13]. Reports 
indicate that ESE-15-ol prevents extracellular acidifica-
tion in MDA-MB-231 cells due to CAIX expression, sug-
gesting that the compound has the potential to curtail 
metastatic processes associated with acidotic micro-envi-
ronmental conditions in tumours [3, 13, 14].
Previous in  vitro crystal violet studies conducted in 
our laboratory revealed optimal antiproliferative activ-
ity exerted by sulphamoylated estradiol derivatives in 
nanomolar concentration range (110–220 nM) in breast 
tumourigenic cell lines (MDA-MB-231 and MCF-7), 
an oesophageal cancer cell line (SNO) and the cervical 
cancer HeLa cell line used in this study [5]. In addition, 
Stander et al. [3] reported that estradiol sulphamoylated 
derivatives inhibited carbonic anhydrase II activity 
between 167 and 180 ± 10 nM [3]. Since these sulpham-
oylated compounds are also hypothesized to be trans-
ported in the blood bound to carbonic anhydrase II, their 
influence on morphology of erythrocytes is noteworthy. 
Ex vivo exposure of 180 nm ESE-15-ol to whole blood for 
24  h revealed no significant erythrocyte morphological 
damage and support future potential for in  vivo studies 
[15].
In this study, the potential anticancer activity of 
ESE-15-ol, a computer-designed potential anticancer 
agent was assessed at a pharmacological concentration 
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(180  nM) and compared to 2ME2 (1  µM, physiological 
concentration) on cell morphology, cell cycle progres-
sion and caspase activation in a cervical cancer cells. 
This merits the efficacy effectiveness of in silico-designed 
potential anticancer compounds for antiproliferative-, 
antimitotic- and apoptotic activity in future development 




The human epithelial cervical cell line (HeLa) was pur-
chased through Sterilab Services (Johannesburg, South 
Africa) from American Tissue Culture Collection (ATCC) 
(Maryland, USA). The HeLa cell line is the oldest and 
utmost circulated immortalized cell line that presents 
with aggressive growth and is derived from cervical ade-
nocarcinoma [16, 17]. HeLa cells were obtained from 
Hendrietta Lacks, a cervical cancer patient in 1951. The 
HeLa cell line is immortal and can divide an infinite num-
ber of times, is aneuploidy with 82 chromosomes and is 
infected with human papillomavirus 18 [18, 19].
All the required reagents of cell culture analyti-
cal grade were purchased from Sigma (St. Louis, USA) 
unless otherwise specified. Sterile cell culture flasks and 
plates were purchased from Sterile lab Services (Kemp-
ton Park, Johannesburg, South Africa). Penicillin, strep-
tomycin, and fungizone were obtained from Highveld 
Biological (Pty) Ltd. (Sandringham, South Africa). The 
Annexin V fluorescein isothiocyanate (FITC) kit was 
purchased from BIOCOM biotech (Pty) Ltd. (Clubview, 
South Africa). 2ME2 was purchased from Sigma Chemi-
cal Co. (St. Louis, MO, USA). ESE-15-ol was synthesized 
by iThemba Pharmaceuticals (Pty) Ltd (Modderfontein, 
Gauteng, South Africa) since compound is not commer-
cially available [5]. Aqueous osmium tetroxide, glutaral-
dehyde, phosphate buffer, quetol, Reynolds’ lead citrate, 
aqueous uranyl acetate and gold were supplied by the 
Electron Microscopy Unit of the University of Pretoria 
from Merck Co. (Munich, Germany). The Cryo-Scanning 
electron microscope (JEOL 840 with Cryostage) and 
the JOEL JEM 2100F transmission electron microscope 
(Electron Microscopy unit, University of Pretoria, South 
Africa) was used for viewing the prepared samples.
Methods
Cell culture
Cells were grown and maintained in 25 cm2 tissue cul-
ture flasks in a humidified atmosphere at 37 °C, 5% car-
bon dioxide (CO2) in a Forma Scientific water-jacketed 
incubator (Ohio, United States of America). HeLa cells 
were routinely cultivated in Dulbecco’s Minimum Essen-
tial Medium Eagle (DMEM) and supplemented with 10% 
heat-inactivated fetal calf serum (FCS) (56  °C, 30  min), 
100 U/ml penicillin G, 100 μg/ml streptomycin, and fun-
gizone (250  μg/ml). A stock solution of 2ME2 (2  μM) 
and ESE-15-ol (10,000  μM) compound dissolved in 
dimethyl sulphoxide (DMSO) were prepared. Both were 
subsequently diluted with medium to the desired con-
centrations before exposure of the cells. The medium of 
control cells was supplemented with an equal volume of 
DMSO (vehicle-treated control). The DMSO content of 
the final dilutions never exceeded 0.024% (v/v). Experi-
ments were conducted in 6-well plates or 25  cm2 cell 
culture flasks.
For 6-well plates, exponentially growing cells were 
seeded at 350,000 cells per well in 3  ml maintenance 
medium on heat-sterilized coverslips. For 25  cm2 
cell culture flasks, exponentially growing HeLa cells 
(1,000,000) were seeded in 25 cm2 flask with a final vol-
ume of 5 ml maintenance medium. After 24 h incubation 
at 37  °C to allow for cell adherence, medium was dis-
carded and cells were exposed to ESE-15-ol and 2ME2 
at the concentrations 180  nM and 1  µM, respectively. 
ESE-15-ol concentration of 180  nM was selected since 
previous studies conducted in our laboratory established 
optimal antiproliferative activity at this dosage (data 
not shown). A 2ME2 concentration of 1  µM was cho-
sen as a previous study demonstrated antiproliferative 
activity the estrogen receptor positive breast epithelial 
adenocarcinoma MCF-7 cell line [10]. The vehicle con-
trol sample composed of DMSO and growth medium 
and the DMSO content of the final dilutions never 
exceeded 0.05% (v/v) and was exposed for 24 h for all the 
experiments.
Polarization‑optical transmitted light differential 
interference contrast
Polarization-optical transmitted light differential inter-
ference contrast (PlasDIC) is a method where the cells 
are illuminated with non-polarized light rendering 
improved contrast and a clear image [17, 20–22]. Plas-
DIC provides reproducibly high-quality imaging of indi-
vidual cells, cell clusters creating a relief-type impression 
regardless of the of the plastic cell culture vessels thick-
ness compared to the glass-bottom vessels required for 
differential interference contrast techniques [17, 18]. 
Images were captured before and after the exposure by 
means of the Axiovert 40  CFL microscope (Carl Zeiss, 
Gottingen, Germany).
Transmission electron microscopy
Transmission electron microscopy was used to evalu-
ate the influence of ESE-15-ol on the internal cellular 
structure. Cells were seeded (1,000,000) in a 25 cm2 flask 
with an overnight attachment policy [23]. Subsequently, 
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medium was discarded and cells were exposed to the 
compounds. After 24 h, cells were trypsinized and resus-
pended in 1 ml medium. Cells were then fixed with 2.5% 
glutaraldehyde in 0.075  M phosphate buffer for 1  h, 
rinsed thrice with 0.075  M phosphate buffer, fixed with 
osmium tetroxide for 30 min, rinsed thrice with distilled 
water and dehydrated with increasing ethanol concentra-
tions (30, 50, 70, 90, and 100%) [23]. Cells were then infil-
trated with 50% quetol in ethanol for 1 h and then with 
100% quetol for 4–6 h. Ultra-thin sections was prepared 
using a microtome and contrasted by means of 4% uranyl 
acetate-staining for 10 min and rinsed with water. Images 
were taken using JOEL JEM 2100F transmission electron 
microscope (Electron Microscopy Unit, University of 
Pretoria, Pretoria, South Africa) [23].
Scanning electron microscopy
Scanning electron microscopy (SEM) was used to deter-
mine the effect of ESE-15-ol on the morphology on the 
cell surface [23]. Cells were seeded at 300,000 cells per 
well on heat-sterilized coverslips in 6-well plates. After 
24 h, and to allow for attachment, cells were exposed to 
the compounds (2ME2, ESE-15-ol) and incubated for 
24 h. Cells were fixed in 2.5% glutaraldehyde in 0.075 M 
phosphate buffer for 1  h and rinsed 3 times for 5  min 
each with 0.075 M phosphate buffer. Cells were fixed in 
0.25% aqueous osmium tetroxide for 30 min and rinsed 
three times in distilled water in a fume cupboard. Sam-
ples were dehydrated with increasing concentrations of 
ethanol (30, 50, 70, 90, 100, 100 and 100%). Samples were 
covered in hexamethyldisilazane, left to dry in a dessica-
tor overnight, sputter-coated in gold and viewed under a 
JSM 840 Scanning Electron Microscope JEOUL, Tokyo, 
Japan [23].
Cell cycle progression
Cell cycle distribution and the detection of a sub-G1 
apoptotic peak were analysed by flow cytometry using 
propidium iodide (PI) that stains deoxyribonucleic acid 
(DNA) [8]. HeLa cells (1,000,000) were seeded in 25 cm2 
flask. After 24  h the medium was discarded and cells 
were exposed to 1 μM 2ME2 and 180 nM ESE-15-ol for 
24  h in 5  ml, respectively. Cells were trypsinized and 
resuspended in 1  ml growth medium. Samples were 
centrifuged for 5  min at 300×g in order to pellet them. 
The supernatant was discarded and samples were resus-
pended in 200  μl of ice-cold phosphate buffer saline 
(PBS) containing 0.1% FCS. Ice-cold 70% ethanol (4 ml) 
was added in a drop wise manner on a vortex in order to 
avoid cell clumping. Samples were stored at 4 °C for 24 h. 
After 24  h cells were pelleted by centrifuging the cells 
at 300×g for 5 min. Supernatant was removed and cells 
were resuspended in 1 ml of PBS containing 40 μg/ml PI, 
0.1% triton X-100 and 100 μg/ml RNase A. The solution 
was incubated at 37  °C, 5% CO2 for 45  min. PI fluores-
cence (relative DNA content per cell) was measured with 
a FC500 System flow cytometer [Beckman Coulter South 
Africa (Pty) Ltd.] equipped with an air-cooled argon laser 
excited at 488  nm. Data from at least 10,000 cells were 
analyzed with CXP software [Beckman Coulter South 
Africa (Pty) Ltd]. Data from cell debris (particles smaller 
than apoptotic bodies) and clumps of two or more cells 
were removed from further analysis. Cell cycle distribu-
tion was generated from the histograms by the Cyflogic 
version 1.2.1 software (Pertu Therho, Turko, Finland). 
Results were expressed as a percentage of the cells in 
each phase.
Annexin V‑FITC/propidium iodide staining
Apoptotic cells have exposed phosphatidylserine mol-
ecules that bind annexin V, while necrotic cells have 
compromised membranes and thus take up PI. Four dif-
ferent populations of cells were distinguished: those that 
were unlabelled (viable cells), those that have bound 
annexin V-FITC only (early apoptotic), those that have 
been stained with PI (necrotic) and those that have both 
bound annexin V and been labelled with PI (late apop-
totic/necrotic cells) [24]. Analysis was performed using 
the BioVision Annexin V-FITC reagent kit acquired 
from BioVision Research Products (Mountain view, 
California, USA). The 1X binding buffer (supplied in 
the kit) was prepared as directed. HeLa cells (1,000,000) 
were seeded in 25  cm2 flask. After 24  h, the medium 
was discarded and the cells were exposed to 1 μM 2ME2 
and 180  nM ESE-15-ol for 24  h in 5  ml, respectively. 
Cells were trypsinized and resuspended in 1 ml PBS for 
washing and samples were centrifuged at 300×g. The 
supernatant collected was discarded and the pellet was 
again washed twice with 1 ml of 1X binding buffer, and 
centrifuged at 300×g for 10 min. Cells were than resus-
pended in 100  μl of 1X binding buffer. Staining was 
done by adding annexin V-FITC (10 μl) for 15 min room 
temperature in the dark. Cells were washed by adding 
1 ml of 1X binding buffer and thereafter cells were cen-
trifuged at 300×g for 10  min. Cells were resuspended 
in 500  μl of  1X binding buffer solution. Subsequently, 
5 μl of PI (100 µg/ml) was added and samples were gen-
tly mixed. Annexin V (FL1) and PI (FL3) fluorescence 
were measured in 10,000 cells per sample with a FC500 
System flow cytometer [Beckman Coulter South Africa 
(Pty) Ltd.] equipped with an air-cooled argon laser 
excited at 488  nm. Results were analysed in Cyflogic 
version 1.2.1 software (Pertu Therho, Turko, Finland) 
statistics and expressed as a percentage of cells in three 
categories namely; viable cells, early apoptotic cells, late 
apoptosis and necrotic cells.
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Caspase 8 activity
Apoptosis is a controlled process resulting in cell death 
that relies on caspase-dependent proteolytic cascade 
resulting in the demise of the cell. Apoptosis is gener-
ally categorized as one of three modes namely, intrinsic 
(also known as the mitochondrial pathway), extrinsic 
(also known as death receptor pathway) and the endo-
plasmic pathway [25, 26]. The intrinsic pathway is trig-
gered by irradiation, starvation and chemicals and takes 
part via mitochondrial involvement. It is characterised 
by mitochondrial outer membrane permeabilization and 
activation of initiator caspase 9 [26, 27]. The endoplasmic 
reticulum pathway is independent of the mitochondria. 
Any stress including oxidative stress, accumulation of 
misfolded proteins leads to endoplasmic reticulum stress 
that possibly results in apoptosis via caspase 12 [28, 29]. 
The extrinsic apoptosis pathway is initiated by the bind-
ing of a death ligand to a death receptor resulting in the 
activation of initiator caspase 8 [30]. The activation of 
caspase 8 was determined using a FLICE/caspase 8 col-
orimetric kit [31]. HeLa cells (1,000,000) were seeded in 
25 cm2 flask. After 24 h the medium was discarded and 
cells were exposed to 1 μM 2ME2 and 180 nM ESE-15-ol 
for 24 h in 5 ml, respectively. After 24 h exposure to 1 μM 
2ME2 and 180  nM ESE-15-ol cells were detached with 
trypsin and centrifuged at 13,000×g. Cells were resus-
pended in 50 µl of chilled cell lysis buffer and incubated 
on ice for 10 min. Cells were centrifuged at 10,000×g for 
1  min. Supernatant was transferred to a fresh tube and 
put on ice. After determination the protein concentra-
tion using the bicinchoninic acid (BCA) protein assay 
(Thermo Fisher Scientific, Johannesburg, South Africa), 
100  µg protein/50  µl cell lysis buffer was mixed with 
50 µl 2X reaction buffer [containing 10 mM Dithiothrei-
tol (DTT)]. The caspase-specific substrate, 5  µl 4  mM 
Ac-Ile-Glu-Thr-Asp-p-nitroanilide (Ac-IETD-pNA) 
was added and the mixture was incubated at 37  °C for 
120  min (200  µM final concentration). Absorbance was 
determined at 405 nm on the EL×800 Universal Micro-
plate Reader available from Bio-Tek Instruments Inc. 
(Vermont, USA).
Statistical analysis of data
Data were obtained from at least three biological repeats 
for all experiments. Quantitative data consisted out of 
cell cycle analysis, annexin V-FITC and caspase 8 assess-
ments. Qualitative data were obtained by means of 
PlasDIC, transmission electron microscopy and SEM. 
Quantitative data were statistically analyzed for signifi-
cance using the Student’s t test. P values of <0.05 were 
regarded as statistically significant. Means were repre-
sented in bar charts with T-bars referring to standard 
deviations. Qualitative experiments were repeated at 
least thrice where data was obtained from PlasDIC, TEM 
and SEM. Regarding flow cytometry data from at least 
10,000 events was analyzed using Cyflogic 1.2.1 software 
(Pertu Terho & Cyflo Ltd.).
Results
Polarization‑optical transmitted light differential 
interference contrast
PlasDIC was used to view morphology after exposure to 
180 nM ESE-15-ol and 1 µM 2ME2 for 24 h in HeLa cells 
when compared to cells propagated in growth medium 
and vehicle-treated cells (Fig.  1). These concentrations 
were used since previous studies conducted in our labo-
ratory demonstrated optimal antiproliferative activity at 
these respective concentrations. ESE-15-ol and 2ME2-
treated HeLa cells demonstrated cell rounding and 
reduced cell density when compared to cells propagated 
in growth medium and 0.024% vehicle-treated cells.
Transmission electron microscopy
Transmission electron microscopy was used to demon-
strate effects on the internal cellular structure after expo-
sure to 180 nM ESE-15-ol and 1 μM 2ME2 on HeLa cells 
(Fig.  2). HeLa cells propagated in growth medium and 
vehicle-treated control cells exhibited normal nuclear 
membrane and cytoplasm, with no sign of distress. ESE-
15-ol and 2ME2 exposure resulted in the formation of 
vacuoles and apoptotic bodies.
Scanning electron microscopy
SEM was used to show the effects of 180 nM ESE-15-ol 
and 1  μM 2ME2 on the cell surface morphology. Cells 
propagated in growth medium and vehicle-treated cells 
were confluent with no signs of distress (Fig.  3). Cells 
exposed to ESE-15-ol and 2ME2 demonstrated decreased 
cell density, rounded cells and apoptotic bodies.
Cell cycle progression
Flow cytometry was used to determine the effect of 
180  nM ESE-15-ol and 1  μM 2  ME2 on cell cycle pro-
gression (Figs.  4, 5; Table  1). Results were calculated as 
percentage cells in each stage of the cell cycle. Cell cycle 
distribution of the cells propagated in growth medium 
revealed an average of 0.88% in sub-G1 population, 58% 
in the G1 phase, 13% in the S phase and 28% in the G2M 
phase. The vehicle-treated sample revealed an average of 
0.75% in sub-G1 population, 59% in the G1 phase, 13% 
in the S phase and 28% in the G2M phase representing 
a cell population in logarithmic growth. A statistically 
significant increase of 17% cells in sub-G1 was demon-
strated in ESE-15-ol treated cells. ESE-15-ol-treated cells 
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showed a decrease in G1-(5%) and S phase (7%) and a dis-
tinct increase of cells in the G2M phase (72%) indicating 
an increase in cells present in a metaphase block. 2ME2-
treated cells presented with 7% cells in sub-G1, 66% cells 
in G1 phase, 8% cells in S phase and 19% of cells in G2M 
phase.
Annexin V‑FITC/propidium iodide staining
The presence of cells in apoptosis was investigated by 
means of flow cytometry and Annexin V-FITC (Fig.  6; 
Table  2). HeLa cells propagated in growth medium and 
0.024% vehicle-treated cells showed intact cell membrane 
and no sign of apoptosis with 97% being viable. HeLa 
cells exposed to ESE-15-ol showed decreased cell viabil-
ity (25%) accompanied with an increase in cells present in 
early apoptotic cells (41%), late apoptotic cells (15%) and 
necrotic cells (19%). 2ME2-treated cells presented with 
48% viable cells, 26% early apoptotic cells, 15% late apop-
totic cells and 11% necrotic cells.
Caspase 8 activity
Influence of 180  nM ESE-15-ol and 1  μM 2ME2 (24  h) 
on caspase 8 activity was investigated by means spectro-
photometry (Fig. 7). The ratio of caspase 8 activities was 
measured with reference to cells propagated in growth 
medium. There was no statistically significant difference 
with regard to caspase 8 activity in vehicle-treated cells 
when compared to cells propagated in growth medium. 
The ESE-15-ol-treated sample showed a 1.7-fold increase 
in caspase 8 activity when compared to cells propagated 
in growth medium. 2ME2-treated sample showed two-
fold increase compared to cells propagated in growth 
medium (Fig. 7).
Discussion
Computer modelling techniques benefit the drug devel-
opment industry since this approach reduces the cost 
of drug development by 50% [32]. In silico-design pro-
cess takes into account parameters such as activity, 
Fig. 1 PlasDIC micrographs demonstrating effects on cell density and cell rounding. PlasDIC micrographs of HeLa cells after 24 h exposure at 20× 
magnification a HeLa cells propagated in growth medium and b vehicle-treated control exposure demonstrated confluent HeLa cells. HeLa cells 
exposed to c 180 nM ESE-15-ol and d 1 μM 2ME2 for 24 h results demonstrated a reduction in cell density and rounded shrunken cells
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absorption, distribution, metabolism and excretion and 
has resulted in a rational drug identification tool [33]. 
However, in silico-design methods are still computer-
based and can’t be directly extrapolated to the efficacy 
of the compound. Computer-based technologies rely 
on algorithms that utilize perfect standards and they 
are not comparable to the biological complexities [34]. 
Thus, in vitro assessments laboratory testing of these in 
silico-designed compounds are essential. This study thus 
evaluated whether an in silico-designed compound (ESE-
15-ol) is as effective as docking- and receptor modelling 
predicts.
Previous research has revealed that 2ME2 plays a cru-
cial role in the induction of apoptosis [8, 35–37]. Due to 
the limited metabolic accessibility and rapid degradation 
of 2ME2, research in our laboratory in silico-designed 
and subsequently synthesized novel 2ME2 analogues 
based on the notion that sulphamate addition increased 
oestrogenic bioavailability by avoiding hepatic first-pass 
hepatic metabolism [38]. Therefore, a 2ME2 analogue, 
ESE-15-ol was in silico-designed in our laboratory [3]. 
Dose-dependent studies were conducted in our labora-
tory and the optimal antiproliferative activity in HeLa 
cells were established at 180 nM of ESE-15-ol (data not 
shown). Several additional 2ME2 analogues exerted 
antiproliferative activity within this concentration range 
(200 nM–1 µM) in cell lines including the MCF-7 cell line 
and esophageal carcinoma SNO cells [11, 39].
Morphological studies of cells exposed to 180  nM 
ESE-15-ol and 1  μM 2ME2 for 24  h showed decreased 
cell density, apoptotic bodies, ghost cells, rounded and 
shrunken cells and cell debris. Previous studies indicated 
that morphological characteristics of exposure to another 
2ME2 analogue, namely 2-ethyl-3-O-sulphamoyl-estra-
1,3,5(10)16-tetraene (ESE-16) included cell shrinkage, 
membrane blebbing condensation of nuclear chroma-
tin into sharply delineated masses that become margin-
ated against the nuclear membrane, vacuolar formation, 
Fig. 2 Transmission electron microscopy showing the internal cellular structure. Transmission electron microscopy of HeLa cells at 
(5 μm × 12,000×) magnification propagated in growth medium (a) and vehicle-treated (b) represented intact nuclear membrane. The 180 nM ESE-
15-ol-treated cells (c) and 1 μM 2ME2-treated cells (d) after exposure for 24 h demonstrated apoptotic bodies and vesicle formation
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shrunken round cells, decreased cell density, cell debris, 
cell distress as well as formation of apoptotic bodies 
[11]. Sulphamoylated 2ME2 analogues exposed to HeLa 
cells and 2-methoxyestradiol-bis-sulphamate exposed 
in MCF-7 cells showed in vitro cytotoxic effect, but did 
not reflect possible damage to cell membrane integ-
rity [38]. Thus, according to morphological evidence 
ESE-15-ol behave in a similar manner to 2ME2, but at a 
pharmacological concentration indicating an improved 
bioavailability.
Cell cycle progression analysis of ESE-15-ol-treated 
HeLa cells showed a G2M block, as well as increase in 
sub-G1 fraction when compared to growth medium and 
vehicle-treated control cells and 2ME2. Exposure of ovar-
ian and prostate cancer cells to another sulphamoylated 
2ME2 analogue, namely 2-methoxyestradiol-bis-sulpha-
mate and ESE-16-exposed MDA-MB-231 cells and ESE-
16-exposed HeLa cells for 24  h showed an increase in 
both G2M block and sub-G1 fraction. After 48 h, nearly 
all the cells were present in the sub-G1 fraction [5, 38, 
Fig. 3 Scanning electron microscope demonstrating effects on the cell surface. Scanning electron microscopy of HeLa cells after exposure to 
growth medium (a) and DMSO vehicle-treated (b) control cells exposure demonstrated confluent growth of HeLa cells. Cells exposed to ESE-15-ol 
(c) and 2ME2 (d) demonstrated decreased cell density, rounded cells and apoptotic bodies
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39]. Exposure to both ESE-15-ol and 2ME2 resulted in 
a decreased percentage of cells occupying the S phase. 
A number of intra-S-phase-related checkpoint proteins 
involved in DNA repair were downregulated in 2ME2-
treated MCF-7 cells which indicated that cells are most 
likely to re-enter mitosis cycle [10].
Flow cytometry study using annexin V-FITC and PI 
demonstrated that ESE-15-ol and 2ME2 resulted in the 
induction of apoptosis. However, the apoptotic activity 
exerted by ESE-15-ol is more prominent at a pharmaco-
logical concentration of 180  nM when compared to the 
apoptotic activity induced by 2ME2 at physiological con-
centration of 1 μM. Theron et al. [11] reported that HeLa 
cells exposed to ESE-16 showed loss of cell membrane 
asymmetry occurring with the translocation of phos-
phatidylserine to the outside of the cell during apoptosis 
induction [11]. 2ME2 has been implicated in induction of 
the apoptotic pathway in several cell lines [39, 40]. Simi-
lar to our study, ESE-16-treated HeLa cells at 0.5 μM also 
showed upregulation in caspase 8 activity [38]. The anal-
ysis of caspase 8 activity demonstrated a twofold increase 
in 1  μM 2ME2-treated cells and a 1.7-fold increase in 
Fig. 4 Histograms of ethanol fixation and PI staining used for cell cycle progression. Cell cycle analyses of cells propagated in growth medium (a), 
0.024% vehicle-treated cells (b), 180 nM ESE-15-ol-treated cells (c) and 1 μM 2 ME2-treated cells (d). The sub-G1 population increased to 17% when 
exposed to ESE-15-ol and 7% after exposure to 2ME2. In addition, exposure to ESE-15-ol resulted in an increased number of cells occupying G2M 
phase (72%) when compared to vehicle-treated cells and cells propagated in growth medium
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180 nM ESE-15-ol-treated cells. This study is the first to 
indicate that the novel in silico-designed estradiol ana-
logue, ESE-15-ol, may act with improved potency as a 
potential anticancer agent when compared to 2ME2 at 
a lower dose. Both the source molecule and its analogue 
resulted in a statistically significant increase in caspase 8 
activity demonstrating the involvement of apoptosis.
Conclusion
The role of computational biology is becoming increas-
ingly important in drug design. It remains challenging to 
accurately predict pharmacological parameters including 
activity and toxicology of these in silico-designed com-
pounds. By combining structural information and in vitro 
studies a predictive tool on possible biological responses 
are provided [41]. Data from this in vitro study supports 
the concept that ESE-15-ol induced apoptosis in cervical 
Fig. 5 Percentage of cells occupying each cell cycle phase. Cell cycle progression of cells propagated in growth medium, 0.024% vehicle-treated 
cells, 180 nM ESE-15-ol-treated cells and 1 μM 2ME2-treated cells. Exposure to both ESE-15-ol and 2ME2 resulted in an increased sub-G1 peak. How-
ever, only exposure to ESE-15-ol resulted in a significant increase in cells occupying the G2M phase (an asterisk indicates P  < 0.05 when compared 
to 2ME2-treated cells)
Table 1 Cell cycle progression using flow cytometry, etha-
nol fixation and PI staining
* Indicates P < 0.05 when compared to 2ME2-treated cells
Sub‑G1 (%) G1 (%) S (%) G2M (%)
Cells propagated in growth 
medium
0.88 58 13 28
Vehicle-treated cells 0.75 59 13 28
ESE-15-ol-treated cells 17* 5* 7 72*
2ME2-treated cells 7 66 8 19
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adenocarcinoma (HeLa) cells in response to an increase 
in the G2M block accompanied with increased caspase 
8 activity demonstrating the induction of the apoptotic 
pathway. In this study it was also demonstrated that ESE-
15-ol exerted increased potent anticancer activity when 
compared to 2ME2. This confirms that in silico-designed 
Fig. 6 Annexin V-FITC and PI staining showing apoptosis induction. Flow cytometry using annexin V-FITC and PI staining of cells propagated in 
growth medium (a), 0.024% vehicle-treated control (b), 180 nM ESE-15-ol-treated cells (c) and 1 μM 2ME2-treated cells (d). Exposure to ESE-15-ol 
and 2ME2 resulted in significant loss of viability (P < 0.05). ESE-15-ol-treated cells presented with 25% viable cells, 41% early apoptotic cells, 15% late 
apoptotic cells and 19% necrotic cells. 2ME2-treated cells presented with 48% viable cells, 26% early apoptotic cells, 15% late apoptotic cells and 
11% necrotic cells
Table 2 Flow cytometry using annexin V-FITC demonstrating viable cells, cells in early apoptosis, cells in late apoptosis 
and necrotic cells
* Indicates P < 0.05 when compared to 2ME2-treated cells
Viable cells (%) Early apoptosis (%) Late apoptosis (%) Necrosis (%)
Cells propagated in growth medium 98 0.98 0 1
Vehicle-treated cells 98 1 0 1
ESE-15-ol-treated cells 25* 41* 15 19*
2ME2-treated cells 48 26 15 11
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identification is effective to assess mechanism of action 
of in silico-designed potential anticancer compounds of 
cell death induction via apoptosis.
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